Professor Powell is Deputy chair of the British Society of Gastroenterology IBD Clinical Research Group. He chaired the British Society of Gastroenterology endorsed guidance on the management of immune-checkpoint inhibitor induced colitis (Powell Lancet Gastroenterology & Hepatology 2021), and the British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement on SARS-CoV2 Vaccination (Alexander Lancet Gastroenterology & Hepatology 2021). He is a member of the Scientific Advisory Group member (oncology) for the European Medicines Agency and a member of several international Clinical Trial Steering Committees for IBD studies (including IM011023, IM011024, IM011127). He has chaired and participated as an advisory consultant in global and national advisory boards for industry partners, including Abbvie, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, DebioPharm, Ferring, Janssen, Roche. Professor Powell is the Integrated Academic Training lead for Gastroenterology at Imperial and the co-lead for the Digestive Diseases theme of Imperial’s Biomedical Research Centre. Professor Powell is a panel member of the Medical Research Awards and Medical adviser for the patient facing charity Crohn’s and Colitis UK.